[Biological engineering for new asthma therapy].
Van Hage
Marianne
M
Avdelningen för klinisk immunologi och transfusionsmedicin, Karolinska Universitetssjukhuset Solna. marianne.van.hage@ki.se
Grönlund
Hans
H
Gafvelin
Guro
G
D000485:Allergens / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D000595:Amino Acid Sequence; D018927:Anti-Asthmatic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D007155:Immunologic Factors / Q000737:chemistry / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D016896:Treatment Outcome; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use
D000485:Allergens; D018927:Anti-Asthmatic Agents; D007155:Immunologic Factors; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic